Ann: Webcast slides for eftilagimod alpha (IMP321), page-36

Also Ahjay, the last question that was raised at the recent company update has really peaked my interest.
Clive Tompkins: OK. We got a question from Jason McCarthy. I'm gonna read it out because Jason's having problems with his microphone. Here's the question: "As it relates to the AIPAC study in breast cancer with much of the focus in our view on melanoma and other programs in partnerships. This trial is the most advanced and heading towards what could be a significant readout that could lead to registration. Can you discuss where enrollment is and are there ongoing partnering discussions for Europe? And what are the plans for development in the US?"

Marc Voigt: Right. In terms of AIPAC, recruitment is mentioned more than 200 patients recruited from out of 226, so we're actually very close. We cannot comment on any potential partnering discussions. I think that our collaborations with the industry, with GSK Novartis, Merck, Pfizer and also German Merck is showing that we know our customer. That's our business model, to license at the right point in time. But of course I can't comment on that specifically.

The US of course a key market for us, for eftilagimod and for everyone in the industry of course. We look for appropriate ways to bridge AIPAC into the United States. There is a number of different possibilities, opportunities we are discussing, and have been discussing already with the regulators. And we will inform the public once these plans are more mature. - end

Now to me, this speaks volumes that its not a matter of if, but when we see licence and partnering deals for our beloved Immutep.
Watch this space